Phylogica Limited
(ASX:PYC), Director, Nick Woolf talks to us about the company’s recently signed alliance with AstraZeneca to pursue antimicrobial peptide discovery and the decision to shift Phylogica’s business model away from in-house drug discovery to contract drug discovery.
Mr Woolf also gives us an update on the company’s partnership with Swiss pharmaceutical giant Roche and whether the company has garnered interest from other major pharmaceutical companies in its peptide library.
And lastly Mr Woolf takes us though the details of a recently announced rights issue to raise $2.4 million and what’s ahead for the company in the next 12 to 18 months.
